| Original language | English (US) |
|---|---|
| Article number | 100446 |
| Journal | Kidney Medicine |
| Volume | 4 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2022 |
Funding
This work was supported by the George M. O’Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Srivastava is supported by NIH grants K23DK120811 and U01AI163081, Kidney Precision Medicine Project Opportunity Pool grant under award U2CDK114886, and core resources from the George M. O’Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Laura Nishi, DScPAS, Cybele Ghossein, MD, and Anand Srivastava, MD, MPH. This work was supported by the George M. O'Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Srivastava is supported by NIH grants K23DK120811 and U01AI163081, Kidney Precision Medicine Project Opportunity Pool grant under award U2CDK114886, and core resources from the George M. O'Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Srivastava reports personal fees from Horizon Therapeutics PLC, CVS Caremark, AstraZeneca, Bayer, and Tate & Latham (medicolegal consulting). Dr Ghossein reports to be local PI on Chemocentryx and Travere studies and has been on a scientific advisory board for Horizon Therapeutics. Dr Nishi declares that she has no relevant financial interests. Received November 3, 2021. Evaluated by 1 external peer reviewer, with direct editorial input from the Editor-in-Chief. Accepted in revised form January 15, 2022.
ASJC Scopus subject areas
- Internal Medicine
- Nephrology
